Palvella Therapeutics (PVLA) Accumulated Expenses: 2013-2024
Historic Accumulated Expenses for Palvella Therapeutics (PVLA) over the last 9 years, with Sep 2024 value amounting to $3.5 million.
- Palvella Therapeutics' Accumulated Expenses fell 72.95% to $3.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $3.5 million, marking a year-over-year decrease of 72.95%. This contributed to the annual value of $1.4 million for FY2023, which is 86.75% down from last year.
- According to the latest figures from Q3 2024, Palvella Therapeutics' Accumulated Expenses is $3.5 million, which was down 35.78% from $5.4 million recorded in Q2 2024.
- In the past 5 years, Palvella Therapeutics' Accumulated Expenses registered a high of $19.7 million during Q3 2021, and its lowest value of $1.4 million during Q4 2023.
- Moreover, its 3-year median value for Accumulated Expenses was $9.1 million (2023), whereas its average is $7.8 million.
- As far as peak fluctuations go, Palvella Therapeutics' Accumulated Expenses surged by 170.67% in 2021, and later tumbled by 86.75% in 2023.
- Over the past 5 years, Palvella Therapeutics' Accumulated Expenses (Quarterly) stood at $7.7 million in 2020, then soared by 117.77% to $16.8 million in 2021, then slumped by 36.17% to $10.7 million in 2022, then crashed by 86.75% to $1.4 million in 2023, then crashed by 72.95% to $3.5 million in 2024.
- Its last three reported values are $3.5 million in Q3 2024, $5.4 million for Q2 2024, and $6.0 million during Q1 2024.